South Korea’s MFDS Reiterates Ban on Gymnema Sylvestre, Bacopa in Supplements

Why It Matters

The crackdown highlights regulatory risks for global supplement exporters and underscores the need for rigorous ingredient verification, especially as Korean consumers increasingly turn to online sources for chronic‑disease remedies.

Key Takeaways

• 12 banned ingredients found in 18 of 30 inspected supplements.
• Gymnema sylvestre linked to drug‑induced hepatitis and hypoglycemia risk.
• Lovastatin detected, classified as prescription drug in Korea.
• MFDS blocked imports and urged customs to suspend clearance.
• Over 4,600 banned‑ingredient products listed on MFDS website as of April 2026.

Pulse Analysis

The South Korean Ministry of Food and Drug Safety (MFDS) continues to enforce one of the world’s strictest import bans on health‑supplement ingredients. Under Article 25‑3 of the Special Act on the Safety Management of Imported Food, more than 300 substances—including narcotics, medicinal compounds and certain botanicals—are prohibited from entering the Korean market. This regulatory framework reflects the country’s high prevalence of chronic diseases; nearly 29 % of adults have hypertension, 27 % hypercholesterolemia and 13 % diabetes, creating strong demand for “miracle” supplements that often skirt safety standards.

In a recent sweep of 30 overseas‑manufactured products sold on platforms such as Amazon and eBay, MFDS investigators identified 12 banned ingredients in 18 items. The list featured herbal extracts like Gymnema sylvestre and Bacopa, mineral‑rich shilajit, and prescription‑only drugs such as lovastatin and L‑citrulline. Health experts warn that Gymnema can trigger drug‑induced hepatitis and dangerous hypoglycemia when combined with insulin, while lovastatin may cause rhabdomyolysis. Following the findings, customs halted clearance of the products and the Communications Standards Commission moved to block related webpages.

The episode sends a clear signal to supplement manufacturers and distributors worldwide: compliance with Korean import rules is non‑negotiable, and reliance on third‑party e‑commerce channels does not shield companies from scrutiny. Firms must implement robust supply‑chain audits, transparent labeling and pre‑market testing to avoid costly product seizures and reputational damage. For Korean consumers, the MFDS’s public database—now listing over 4,600 prohibited‑ingredient products—offers a valuable tool to verify product safety before purchase, potentially curbing the growth of unverified health claims in the market.